

## Targeted Cancer Panel (R444.1): NICE approved PARP inhibitor treatment

Please complete **ALL** sections and send to [geneticlabs@belfasttrust.hscni.net](mailto:geneticlabs@belfasttrust.hscni.net) or send a copy to the Regional Molecular Diagnostic Service, Belfast City Hospital. **This must be accompanied by our standard genetics blood collection form and patient consent**

Clinical genetics enquiries	Email: <a href="mailto:genetic.medicine@belfasttrust.hscni.net">genetic.medicine@belfasttrust.hscni.net</a>	Tel: 028 9504 8022
Lab enquiries	Email: <a href="mailto:geneticlabs@belfasttrust.hscni.net">geneticlabs@belfasttrust.hscni.net</a>	Tel: 028 9504 7353

### Patient Details

Full name:	DoB:
H&C no:	Ethnicity:
Diagnosis:	Age at diagnosis:

Further personal/family history of cancer:

### Referring Clinician Details- note referrals without a named consultant will be refused

Consultant oncologist Breast surgeon Other- please specify below _____	Full name: Hospital/Dept: Email: Consultant:
---	---

### Indication for testing - patient **must** meet one of the following (tick as appropriate)

Note this testing criteria only applies to patients who don't meet R208 criteria AND with a current breast cancer diagnosis for treatment decisions

- Triple negative breast cancer and have received neo-adjuvant chemotherapy:
  - residual invasive cancer in the breast, the resected lymph nodes (non-pathological complete response) or both at the time of surgery
- Triple-negative breast cancer having adjuvant chemotherapy:
  - node-positive OR node-negative cancer with a primary tumour  $\geq 2$  cm
- Hormone receptor-positive, HER2- breast cancer & have received neoadjuvant chemotherapy:
  - residual invasive cancer in the breast, the resected lymph nodes (non-pathologic complete response) or both at the time of surgery, AND a CPS + EG score of  $\geq 3$  based on pre-treatment clinical and posttreatment pathological stage, receptor status and histological grade
- Hormone receptor-positive, HER2-negative breast cancer & having adjuvant chemotherapy:
  - 4 or more pathologically confirmed positive lymph nodes.

### Panel genes: the following genes will be tested for all patients

**Inherited Breast and Ovarian Cancer Panel:**  
 ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

See our [website](https://belfasttrust.hscni.net/service/laboratory-services/clinical-genetics/mainstreaming-cancer-genetics/breast-cancer-mainstreaming/) for resources and more information about mainstream genetic testing:  
<https://belfasttrust.hscni.net/service/laboratory-services/clinical-genetics/mainstreaming-cancer-genetics/breast-cancer-mainstreaming/>